Atrial Natriuretic Peptide: IS ANP associated with restenosis
after Coronary Artery Disease?

D 2006

Atrial Natriuretic Peptide: IS ANP associated with restenosis after Coronary Artery Disease?

SWAMY, Ganesha, Julie BIENERTOVÁ VAŠKŮ, Petr BIENERT, Ota HLINOMAZ, Anna VAŠKŮ et. al.

Základní údaje

Originální název

Atrial Natriuretic Peptide: IS ANP associated with restenosis after Coronary Artery Disease?

Název česky

Je variabilita v genu pro atriální natriuretický peptid asociována s výskytem restenózy po PCI?

Autoři

SWAMY, Ganesha (826 Velká Británie a Severní Irsko), Julie BIENERTOVÁ VAŠKŮ (203 Česká republika, garant), Petr BIENERT (203 Česká republika), Ota HLINOMAZ (203 Česká republika) a Anna VAŠKŮ (203 Česká republika)

Vydání

Hungary, New Frontiers in Basic Cardiovascular Research, od s. 82-82, 1 s. 2006

Nakladatel

INSERM, France

Další údaje

Jazyk

angličtina

Typ výsledku

Stať ve sborníku

Obor

Genetika a molekulární biologie

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Kód RIV

RIV/00216224:14110/06:00017441

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Atrial natriuretic peptide; restenosis; PCI

Štítky

Atrial natriuretic peptide, PCI, restenosis

Změněno: 2. 11. 2006 15:10, prof. MUDr. Julie Dobrovolná, Ph.D.

Anotace

ORIG CZ

V originále

Background: ANP has shown over recent studies to play an increasingly pivotal role in the regulation of coronary blood flow and atherosclerosis. The gene polymorphism of interest, transition T2238C (ScaI) in the ANP precursor gene, leads to the abolishment of the regular stop codon and instead translation of an additional two arginines. The purpose of the study is to identify the possible influence of ANP ScaI polymorphism on restenotic phenotypes in coronary artery disease (CAD) patients. Method: This study was performed on 96 consecutive caucasians (24 women and 72 men) with clinically significant coronary artery disease confirmed by means of quantitave coronary angiography with minimum one coronary artery with more than 50% lumen stenosis, and all with bare metal stenting in coronary arteries < 3mm. Results: No differences were found in relation to patients with or without restenosis and the genotype distributions as well as allelic frequencies of examined ANP ScaI polymorphism (p = 0.28). However, there is a borderline significant association of ANP genotype distribution with CAD risk factors, such as hypertension and hyperlipidemia (p = 0.05). According to our findings, the allelic frequencies of the ANP ScaI polymorphism in the Czech CAD population do statistically significantly differ from those described in Polish CAD patients (p = 0.01). Conclusion: The ANP ScaI gene polymorphism, based on our data, is not a genetic marker for restenosis after stenting in CAD patients, but the study does suggest that ANP genotypes, specifically A2A2 variants, may be conducive to hypertension. This may be explained by impaired natriuresis in the kidney, perhaps due to reduced affinity or impaired binding of ANP to its receptor, thus leading to sodium retention and increased extracellular volume. Continued research into ANP and its pathophysiological role we believe is imperative to further elucidate how ANP is associated to hypertension.

Česky

Polymorfismus ScaI v genu pro atriální natriuretický peptid se nezdá být velkým faktorem pro rozvoj restenózy po PCI.

Návaznosti

MSM 141100002, záměr

Název: Molekulární patofyziologie multigenních chorob

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Molekulární patofyziologie multigenních chorob

Citovat

SWAMY, Ganesha, Julie BIENERTOVÁ VAŠKŮ, Petr BIENERT, Ota HLINOMAZ a Anna VAŠKŮ. Atrial Natriuretic Peptide: IS ANP associated with restenosis after Coronary Artery Disease? In New Frontiers in Basic Cardiovascular Research. Hungary: INSERM, France, 2006, s. 82-82.

@inproceedings{699945,
   author = {Swamy, Ganesha and Bienertová Vašků, Julie and Bienert, Petr and Hlinomaz, Ota and Vašků, Anna},
   address = {Hungary},
   booktitle = {New Frontiers in Basic Cardiovascular Research},
   keywords = {Atrial natriuretic peptide; restenosis; PCI},
   language = {eng},
   location = {Hungary},
   pages = {82-82},
   publisher = {INSERM, France},
   title = {Atrial Natriuretic Peptide: IS ANP associated with restenosis after Coronary Artery Disease?},
   year = {2006}
}

TY  - JOUR
ID  - 699945
AU  - Swamy, Ganesha - Bienertová Vašků, Julie - Bienert, Petr - Hlinomaz, Ota - Vašků, Anna
PY  - 2006
TI  - Atrial Natriuretic Peptide: IS ANP associated with restenosis after Coronary Artery Disease?
PB  - INSERM, France
CY  - Hungary
KW  - Atrial natriuretic peptide
KW  - restenosis
KW  - PCI
N2  - Background: ANP has shown over recent studies to play an increasingly pivotal role in the regulation of coronary blood flow and atherosclerosis. The gene polymorphism of interest, transition T2238C (ScaI) in the ANP precursor gene, leads to the abolishment of the regular stop codon and instead translation of an additional two arginines. The purpose of the study is to identify the possible influence of ANP ScaI polymorphism on restenotic phenotypes in coronary artery disease (CAD) patients. Method: This study was performed on 96 consecutive caucasians (24 women and 72 men) with clinically significant coronary artery disease confirmed by means of quantitave coronary angiography with minimum one coronary artery with more than 50% lumen stenosis, and all with bare metal stenting in coronary arteries < 3mm. Results: No differences were found in relation to patients with or without restenosis and the genotype distributions as well as allelic frequencies of examined ANP ScaI polymorphism (p = 0.28). However, there is a borderline significant association of ANP genotype distribution with CAD risk factors, such as hypertension and hyperlipidemia (p = 0.05). According to our findings, the allelic frequencies of the ANP ScaI polymorphism in the Czech CAD population do statistically significantly differ from those described in Polish CAD patients (p = 0.01). Conclusion: The ANP ScaI gene polymorphism, based on our data, is not a genetic marker for restenosis after stenting in CAD patients, but the study does suggest that ANP genotypes, specifically A2A2 variants, may be conducive to hypertension. This may be explained by impaired natriuresis in the kidney, perhaps due to reduced affinity or impaired binding of ANP to its receptor, thus leading to sodium retention and increased extracellular volume. Continued research into ANP and its pathophysiological role we believe is imperative to further elucidate how ANP is associated to hypertension.
ER  -

SWAMY, Ganesha, Julie BIENERTOVÁ VAŠKŮ, Petr BIENERT, Ota HLINOMAZ a Anna VAŠKŮ. Atrial Natriuretic Peptide: IS ANP associated with restenosis after Coronary Artery Disease? In \textit{New Frontiers in Basic Cardiovascular Research}. Hungary: INSERM, France, 2006, s.~82-82.

Podrobný výpis o publikaci